| Literature DB >> 36231125 |
Youli Konstantinovitch Stepanov1, Jan Dominik Speidel2, Carola Herrmann2, Nina Schmid2, Rüdiger Behr3, Frank-Michael Köhn4, Jan Bernd Stöckl1, Ulrich Pickl5, Matthias Trottmann5, Thomas Fröhlich1, Artur Mayerhofer2, Harald Welter2.
Abstract
The functions of human testicular peritubular cells (HTPCs), forming a small compartment located between the seminiferous epithelium and the interstitial areas of the testis, are not fully known but go beyond intratesticular sperm transport and include immunological roles. The expression of the glucocorticoid receptor (GR) indicates that they may be regulated by glucocorticoids (GCs). Herein, we studied the consequences of the GC dexamethasone (Dex) in cultured HTPCs, which serves as a unique window into the human testis. We examined changes in cytokines, mainly by qPCR and ELISA. A holistic mass-spectrometry-based proteome analysis of cellular and secreted proteins was also performed. Dex, used in a therapeutic concentration, decreased the transcript level of proinflammatory cytokines, e.g., IL6, IL8 and MCP1. An siRNA-mediated knockdown of GR reduced the actions on IL6. Changes in IL6 were confirmed by ELISA measurements. Of note, Dex also lowered GR levels. The proteomic results revealed strong responses after 24 h (31 significantly altered cellular proteins) and more pronounced ones after 72 h of Dex exposure (30 less abundant and 42 more abundant cellular proteins). Dex also altered the composition of the secretome (33 proteins decreased, 13 increased) after 72 h. Among the regulated proteins were extracellular matrix (ECM) and basement membrane components (e.g., FBLN2, COL1A2 and COL3A1), as well as PTX3 and StAR. These results pinpoint novel, profound effects of Dex in HTPCs. If transferrable to the human testis, changes specifically in ECM and the immunological state of the testis may occur in men upon treatment with Dex for medical reasons.Entities:
Keywords: cytokines; dexamethasone; human male fertility; human testis; proteomics
Mesh:
Substances:
Year: 2022 PMID: 36231125 PMCID: PMC9562650 DOI: 10.3390/cells11193164
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 7.666
Figure 1Consequences of Dex on cytokine levels. (A) HTPCs treated with 1 µM Dex for 48 h responded with the decreased secretion of IL6, IL8, MCP1 and CXCL1 compared to untreated cells (n = 1), as demonstrated by a human cytokine profiler assay. The upper panel shows the corresponding membrane spots of untreated control, while the lower panel depicts Dex (1 µM)-treated HTPCs and reveals a reduction of the signal intensity of IL6, IL8, MCP1 and CXCL1. (B) Using an ELISA, highly significantly decreased IL6 levels could be detected in the culture media of HTPCs from four individual patients treated for 48 h with 1 µM Dex compared to the corresponding control condition. Results were normalized to the total protein amount and statistically analyzed using a paired t-test (two-tailed paired t-test: ** p < 0.01; n = 4). (C) Quantitative PCR revealed significantly decreased mRNA expression levels of IL6, IL8, MCP1, MCP3 and IL1B in HTPCs after 24 h stimulation with 1 µM Dex. CXCL1 transcripts did not change significantly compared to control (ns: not significant, * p < 0.05; n = 4).
Figure 2Regulation of GR by siRNA and Dex. (A) Silencing of GR by siRNA: Two representative GR Western blots from two patients (P1 and P2, n = 2) show the results of HTPCs transfected with non-targeting (NT) control siRNA and GR siRNA (siGR) at two different time points (48 h and 72 h) each and emphasize the efficiency of the transfection with siGR RNA. (B) Transfection of HTPCs with a GR siRNA abolished the observed effect on IL6 and FKBP5 mRNA. Quantitative PCR data of HTPCs from three different patients (n = 3) transfected with a non-targeting control siRNA (siNT) or GR siRNA (siGR) and treated with Dex (1 µM; siNT + Dex and siGR + Dex) or an equal volume of EtOH (Basal Co and Dex) for 24 h are depicted, ## p ≤ 0.01 vs. Co cells; * p ≤ 0.05, ** p ≤ 0.01 vs. siNT + dex cells. (C) Stimulation of HTPCs with Dex led to the downregulation of GR expression. In the presence of 1 µM Dex for 24 h and 48 h, GR protein in HTPCs from two different donors (P1 and P2, n = 2) was downregulated compared to control (Co), as shown by Western blot. In addition, significantly diminished GR (n = 7; upper left picture) but not AR mRNA (n = 9; lower left picture) was detected after 24 h incubation with 1 µM Dex.
Figure 3Volcano plot analysis of cellular proteomes treated with 1 µM dexamethasone for 24 h (A) and 72 h (B). The data was analyzed with a paired Student’s t-test; false-discovery rate (FDR): 0.05. Each colored dot represents a protein fulfilling the significance criteria (q-value < 0.05, log2 fold change >|0.6|): blue–proteins less abundant in the treated group; red–proteins more abundant in the treated group. For selected significant hits, gene names are displayed. (C) = log2 fold changes of significantly differentially abundant proteins of the 24 h-treatment and 72 h-treatment datasets. For the overlap, the 72 proteins (fulfilling the above significance criteria) from 72 h dataset were used as “base”. This was overlayed by the proteins from the 24 h dataset fulfilling only the “overlap criterion” of q-value < 0.05, which additionally includes potential trends, given the lower size of this dataset.
Figure 4Volcano plot of cellular secretomes treated with 1 µM dexamethasone for 24 h (A) and a 72 h (B). The data was analyzed with a paired Student’s t-test; false-discovery rate (FDR): 0.05. Each colored dot represents a protein fulfilling the significance criteria (q-value < 0.05, log2 fold change > |0.6|): blue—proteins less abundant in the treated group; red—proteins more abundant in the treated group. For selected significant hits, gene names are displayed.
Figure A1Regulation of PDGFRalpha (PDGFRa) by Dex. In the presence of 1 µM Dex for 72 h, PDGFRa protein in HTPCs from three donors (P1-P3) was increased, compared to controls (Co), as shown by Western blot.
Figure 5Bioinformatic analysis based on the functional enrichment of all merged (proteome + secretome) significantly differentially abundant proteins (A,B). 24 h-treatment, PROTEOMAPS-based analysis. (a,b): 24 h-treatment, DAVID-based analysis. (C,D): 72 h-treatment, PROTEOMAPS-based analysis. (c,d): 72 h-treatment, DAVID-based analysis. For PROTEOMAPS, proteins were annotated using GO “biological process”. The terms are shown in the legend and comprise all tiles of similar color. Annotated individual proteins are displayed in the mosaic plots. For DAVID analysis, functional enrichment terms GO_BP_all, GO_CC_all, GO_MF_all, KEGG and Reactome were used.
Summary of proteins altered in abundance upon dexamethasone treatment.
|
| ||
| Enriched Term | DAVID Enrichment Score | Annotated proteins |
| IGF II binding | 2.67 | IGFBP5, IGFBP4, IGFBP3 |
| PDGF binding | 2.96 | COL1A1, COL3A1, COL1A2 |
| bone trabecula formation | 3.59 | GREM1, COL1A1, SFRP1, MMP2 |
| negative regulation of peptidase activity | 4.45 | YWHAE, C3, APP, ECM1, LXN, SERPINE2, SERPINH1, SPOCK1, COL6A3 |
| endopeptidase inhibitor activity | 4.48 | C3, APP, LXN, SERPINE2, SERPINH1, SPOCK1, COL6A3 |
| regulation of cell migration | 4.53 | GREM1, COL1A1, COL18A1, COL3A1, ECM1, SFRP1, CEMIP, IGFBP5, SERPINE2, IGFBP3, MSN, CALR |
| collagen catabolic process | 5.37 | COL1A1, COL18A1, COL3A1, COL1A2, MMP2, COL6A3 |
|
| ||
| Enriched term | Annotated proteins | |
| environmental information processing | VCAN, CD248, COL6A3, SFRP1, COL1A1, COL1A2, COL3A1, LAMB2, ITGA11 | |
| genetic information processing | PPP1CC, SERPINH1, TXN, CALR, MMP2, HIST2H4B, NEK7, MAPRE2, SNRPD1, HSPB7 | |
| metabolism | SOD3, SPOCK1, BGN, ALDOA, PGAM1, PKM | |
| organismal system | MSN, TPM4, APP, COL18A1 | |
| cellular processes | VIM, C3, THBS2, YWHAE, IGFBP3, KRT18, CHMP2A | |
|
| ||
| Enriched term | DAVID enrichment score | Annotated proteins |
| focal adhesion | 3.25 | ALCAM, GSN, PALLD, FBLIM1, TGFB1I1, NEXN, SORBS3 |
| basement membrane | 3.48 | LAMA2, COL4A1, LAMB1, NID1 |
| regulation of cell migration | 3.64 | STAT5A, PDGFRA, GSN, LAMA2, SERPINE1, MYADM, NEXN, LAMB1, APOD, DCN |
| extracellular exosome | 5.55 | CPM, GSN, LAMA2, SLC44A1, SERPINE1, LAMB1, NID1, FSTL1, FBLN5, CLEC3B, ALCAM, DNAJB4, MGP, MYADM, SERPING1, AOX1, APOD, CKB, METTL7A, MFGE8, GLUL, FKBP5 |
|
| ||
| Enriched term | Annotated proteins | |
| environmental information processing | ALCAM, NID1, SLC44A1, CTGF, SERPINE1, LAMB1, LAMA2, COL4A1, DCN, STAT5A, PDGFRA | |
| genetic information processing | GGT5, CPM, USP15, DNAJB4 | |
| metabolism | ADH1B, CKB, GLUL, AOX1, PLA2G4A, LOX | |
| organismal system | GSN, SERPING1, FKBP5 | |
| cellular processes | TJP2, MAP2 | |